phrykt

Pacific Biosciences Of California, Inc. (PACB): who owns it and who trades it

As of Nov 16, 2026, PACB insiders reported 12 open-market sales worth $3.4M and no purchases in the last 12 months, with 61% of the sale value made under pre-set 10b5-1 plans. The largest seller was James R Gibson II (See Remarks), with $2.2M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pacific Biosciences Of California

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, PACB insiders reported $0 of open-market purchases and $3.4M of sales. 61% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$3.4M
12 trades, 4 people
Sales under a 10b5-1 plan
61%
Share of sale value
Latest trade
Oct 6, 2026
Filed Oct 8, 2026

Purchases and sales by month

$2.1M$2.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 6, 2026James R Gibson IISee RemarksSale plan661,815$3.11$2.1MForm 4
Aug 17, 2026Oene Mark VanSee RemarksSale26,911$1.13$30.4KForm 4
Apr 1, 2026James R Gibson IISee RemarksSale88,185$1.37$121KForm 4
Mar 3, 2026Christian O HenrySee RemarksSale12,497$1.51$18.9KForm 4
Mar 3, 2026Oene Mark VanSee RemarksSale6,504$1.51$9.8KForm 4
Mar 3, 2026Michele FarmerSee RemarksSale2,979$1.51$4.5KForm 4
Feb 18, 2026Oene Mark VanSee RemarksSale55,107$1.63$89.8KForm 4
Feb 18, 2026Christian O HenrySee RemarksSale140,874$1.63$230KForm 4
Feb 18, 2026Michele FarmerSee RemarksSale14,952$1.63$24.4KForm 4
Feb 17, 2026Oene Mark VanSee RemarksSale129,790$1.58$205KForm 4
Feb 17, 2026Christian O HenrySee RemarksSale331,793$1.58$524KForm 4
Feb 17, 2026Michele FarmerSee RemarksSale35,215$1.58$55.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
James R Gibson IISee Remarks–$2.2MOct 6, 2026
Christian O HenrySee Remarks–$773KMar 3, 2026
Oene Mark VanSee Remarks–$335KAug 17, 2026
Michele FarmerSee Remarks–$84.5KMar 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PACB short interest

High short interest. 17.3% of PACB shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 10%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 53.68M PACB shares were sold short, 17.3% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 12.98M shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short, % of all shares

17.3%May 15Oct 3020.2%

Days to cover

4.1May 15Oct 3011.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202653.68M17.27%+14%12.98M4.1
Oct 15, 202646.93M15.10%-1%21.42M2.2
Sep 30, 202647.22M15.19%-3%15.91M3.0
Sep 15, 202648.89M15.73%-1%4.66M10.5
Aug 31, 202649.58M15.95%-7%7.34M6.8
Aug 14, 202653.41M17.18%+9%8.06M6.6
Jul 31, 202649.00M15.77%+6%6.67M7.3
Jul 15, 202646.24M14.89%-3%4.64M10.0
Jun 30, 202647.49M15.29%-22%7.29M6.5
Jun 15, 202660.56M19.50%+24%5.95M10.2
May 29, 202648.71M15.68%-19%5.68M8.6
May 15, 202659.93M19.29%+27%6.65M9.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pacific Biosciences Of California company events

Pacific Biosciences Of California filed 12 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AgreementPacific Biosciences of California, Inc. entered into a Sales Agreement with Allen & Company LLC to sell shares of the Company’s common stock, par value $0.001 per share, having aggregate sales proceeds of up to $100 million, from time to time, through an “at-the-market” equity offering program… Filing
  2. Nov 4, 2026LeadershipJim Gibson stepped down as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company and transitioned to a non-executive advisory role[ as an advisor to the Chief Executive Officer]. Mr. Gibson is expected to remain employed by the Company in that… Filing
  3. Aug 5, 2026LeadershipThe Board appointed Mark Van Oene, age 54, as the Company’s President and Chief Executive Officer and as a member of the Board, effective August 5, 2026. Filing
  4. Jul 9, 2026LeadershipChristopher M. Smith, a member of the board of directors of Pacific Biosciences of California, Inc., notified the Company of his resignation from the Board, effective immediately. Filing
  5. Jun 4, 2026LeadershipThe board of directors of Pacific Biosciences of California, Inc., at the recommendation of the compensation committee of the Board, approved an amendment to the Company’s 2020 Equity Incentive Plan, subject to stockholder approval, to reserve an additional 16,000,000 shares of the Company’s common… Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 6, 2026LeadershipMichele Farmer notified Pacific Biosciences of California, Inc. that she is voluntarily resigning as Chief Accounting Officer of the Company effective on March 21, 2026, to pursue another opportunity. Filing
  8. Mar 5, 2026LeadershipThe Board of Directors of Pacific Biosciences of California, Inc., upon the recommendation of its Corporate Governance and Nominating Committee, increased the size of the Board to ten directors and appointed Christopher Gibson, Ph.D. to serve as a Class I director effective as of the Effective… Filing
  9. Feb 12, 2026ResultsReleased financial results. Filing
  10. Feb 3, 2026LeadershipPacific Biosciences of California, Inc. announced that, effective January 28, 2026, Mark Van Oene, the Company’s Chief Operating Officer, will on an interim basis assume responsibilities for the Company’s sales and customer support organizations, which were previously assigned to Christian Henry… Filing
  11. Feb 2, 2026DealBelow is hereby incorporated by reference into this Item 1.01. Filing
  12. Jan 12, 2026AnnouncementThe information set forth in the Press Release, solely to the extent such information references the Company’s expectations for preliminary revenue estimates for the quarter and year ended December 31, 2025 and preliminary cash, cash equivalents and investments balance as of December 31, 2025… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pacific Biosciences Of California financials

Famous investors that hold PACB

6 of the 50 well-known investors we track reported holding PACB in their latest 13F filing. The largest position is Cathie Wood's, worth $70.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 202629.75M$70.5M0.4%-0%
Ken Griffin · Citadel AdvisorsQ3 20266.52M$15.4M0.0%+129%
Steve Cohen · Point72 Asset ManagementQ3 20265.59M$13.2M0.0%+17%
Israel Englander · Millennium ManagementQ3 20263.75M$8.9M0.0%-5%
Paul Tudor Jones · Tudor Investment CorpQ3 2026684,707$1.6M0.0%No change
Ray Dalio · Bridgewater AssociatesQ3 202669,747$165K0.0%-32%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PACB in the last 120 days.

FiledHolderFormStake
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G7.6%
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G7.6%
Nov 6, 2026T. Rowe Price Associates, Inc.13G10.8%
Nov 6, 2026T. Rowe Price Associates, Inc.13G10.8%

Questions about Pacific Biosciences Of California, Inc. (PACB) stock

Are PACB insiders buying or selling?

In the last 12 months, PACB insiders reported no open-market purchases and 12 sales worth $3.4M. The latest trade was on Oct 6, 2026. See every trade.

What is the short interest in PACB?

As of Oct 30, 2026, 53.68M PACB shares were sold short, 17.3% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 12.98M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold PACB?

6 of the 50 well-known investors we track reported PACB in their latest 13F filing, including Cathie Wood, Ken Griffin, Steve Cohen. The largest position is worth $70.5M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.